Published in Nat Genet on December 11, 2011
Cancer genome landscapes. Science (2013) 25.33
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Functional impact bias reveals cancer drivers. Nucleic Acids Res (2012) 2.96
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia (2013) 2.85
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet (2012) 2.64
The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature (2015) 2.63
The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov (2012) 2.51
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Pre-mRNA splicing in disease and therapeutics. Trends Mol Med (2012) 2.23
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. Genes Dev (2014) 1.73
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol (2014) 1.58
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell (2015) 1.51
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell (2015) 1.47
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood (2014) 1.44
From human genome to cancer genome: the first decade. Genome Res (2013) 1.42
Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood (2013) 1.34
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia (2012) 1.31
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell (2014) 1.28
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer (2012) 1.27
Myeloid malignancies: mutations, models and management. BMC Cancer (2012) 1.24
Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet (2014) 1.24
Spliceosome mutations in hematopoietic malignancies. Nat Genet (2011) 1.23
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica (2012) 1.13
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia (2013) 1.13
U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res (2014) 1.13
Defects in spliceosomal machinery: a new pathway of leukaemogenesis. Br J Haematol (2012) 1.12
Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica (2013) 1.11
The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today (2012) 1.10
Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest (2014) 1.09
SF3B1 mutations in chronic lymphocytic leukemia. Blood (2013) 1.08
Kinetic competition during the transcription cycle results in stochastic RNA processing. Elife (2014) 1.08
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia (2012) 1.02
Widespread intron retention diversifies most cancer transcriptomes. Genome Med (2015) 1.01
Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med (2013) 1.01
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene (2015) 1.00
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget (2012) 1.00
U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation. Mol Cell (2016) 0.98
U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One (2012) 0.98
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med (2016) 0.97
Defective control of pre-messenger RNA splicing in human disease. J Cell Biol (2016) 0.96
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res (2013) 0.95
Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol (2014) 0.95
Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol (2012) 0.94
Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J (2013) 0.94
RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer (2016) 0.92
Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw (2015) 0.92
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun (2015) 0.92
Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proc Natl Acad Sci U S A (2014) 0.92
Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease. Adv Exp Med Biol (2014) 0.92
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia (2014) 0.91
U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia (2014) 0.91
SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing. Mol Cell Biol (2015) 0.89
The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment. Clin Med Insights Oncol (2014) 0.89
SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. Haematologica (2013) 0.87
Molecular pathogenesis of myelodysplastic syndromes. Transl Med UniSa (2014) 0.86
Cancer-relevant splicing factor CAPERα engages the essential splicing factor SF3b155 in a specific ternary complex. J Biol Chem (2014) 0.85
Therapeutic targeting of splicing in cancer. Nat Med (2016) 0.85
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia (2015) 0.84
Genomics of acute myeloid leukemia: the next generation. Front Oncol (2012) 0.84
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies. Cancer Sci (2015) 0.84
Myelopoiesis and myeloid leukaemogenesis in the zebrafish. Adv Hematol (2012) 0.83
A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Res (2016) 0.82
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol (2013) 0.81
Recent advances in understanding clonal haematopoiesis in aplastic anaemia. Br J Haematol (2017) 0.81
Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates. Pharmacol Res Perspect (2015) 0.81
Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol (2016) 0.81
Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? Haematologica (2012) 0.80
Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev (2016) 0.80
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res (2014) 0.80
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia (2015) 0.80
Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. Oncotarget (2012) 0.80
Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer (2014) 0.79
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations. Oncotarget (2016) 0.79
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol (2016) 0.79
The NLRP3 Inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood (2016) 0.79
Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun (2017) 0.78
Ddx46 is required for multi-lineage differentiation of hematopoietic stem cells in zebrafish. Stem Cells Dev (2013) 0.78
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget (2016) 0.78
Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures. Oncogene (2016) 0.78
Splicing-factor alterations in cancers. RNA (2016) 0.78
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. Haematologica (2012) 0.78
The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts. BMC Cancer (2015) 0.77
How mRNA is misspliced in acute myelogenous leukemia (AML)? Oncotarget (2014) 0.77
Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. Cancer Sci (2014) 0.77
Discovering transcription and splicing networks in myelodysplastic syndromes. PLoS One (2013) 0.77
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia (2016) 0.77
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer (2016) 0.77
Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival. PLoS Genet (2016) 0.76
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics (2009) 16.04
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics (2009) 15.08
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
The spliceosome: design principles of a dynamic RNP machine. Cell (2009) 12.82
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Insertional mutagenesis in zebrafish rapidly identifies genes essential for early vertebrate development. Nat Genet (2002) 5.43
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev (2010) 4.75
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol (2009) 4.18
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Functional recognition of the 3' splice site AG by the splicing factor U2AF35. Nature (1999) 3.72
Recognition of the mRNA AU-rich element by the zinc finger domain of TIS11d. Nat Struct Mol Biol (2004) 3.39
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia (2011) 2.82
Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA (2011) 2.61
Interactions of CCCH zinc finger proteins with mRNA: non-binding tristetraprolin mutants exert an inhibitory effect on degradation of AU-rich element-containing mRNAs. J Biol Chem (2002) 2.17
A novel peptide recognition mode revealed by the X-ray structure of a core U2AF35/U2AF65 heterodimer. Cell (2001) 2.02
Genome-wide survey and expression profiling of CCCH-zinc finger family reveals a functional module in macrophage activation. PLoS One (2008) 1.95
The emerging role of splicing factors in cancer. EMBO Rep (2008) 1.83
Mutations in the small subunit of the Drosophila U2AF splicing factor cause lethality and developmental defects. Proc Natl Acad Sci U S A (1996) 1.60
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One (2009) 1.53
RNA interference knockdown of hU2AF35 impairs cell cycle progression and modulates alternative splicing of Cdc25 transcripts. Mol Biol Cell (2006) 1.49
In vivo requirement of the small subunit of U2AF for recognition of a weak 3' splice site. Mol Cell Biol (2006) 1.33
U2AF35 is encoded by an essential gene clustered in an operon with RRM/cyclophilin in Caenorhabditis elegans. RNA (1999) 1.32
AG-dependent 3'-splice sites are predisposed to aberrant splicing due to a mutation at the first nucleotide of an exon. Nucleic Acids Res (2011) 1.07
The splicing factor U2AF small subunit is functionally conserved between fission yeast and humans. Mol Cell Biol (2004) 1.03
A double-reporter splicing assay for determining splicing efficiency in mammalian cells. Nat Protoc (2006) 0.99
Allele-specific recognition of the 3' splice site of INS intron 1. Hum Genet (2010) 0.94
POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature. Leukemia (2010) 0.90
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res (2005) 44.08
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Whole-genome sequencing and variant discovery in C. elegans. Nat Methods (2008) 31.92
Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
International network of cancer genome projects. Nature (2010) 20.35
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
The B73 maize genome: complexity, diversity, and dynamics. Science (2009) 18.73
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics (2009) 16.04